News

Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
ProMIS reports first human evidence of PMN310 target engagement in Alzheimer’s disease
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
Erasca reports encouraging Phase 1 data for ERAS-0015 and outlines Phase 3 cancer trials
read more
Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development
Tenpoint submits UK application for presbyopia eye drop YUVEZZI
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Q32 Bio reports positive Phase 2 alopecia areata trial results for bempikibart
read more
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Research & Development
Vandria reports Phase 1 data supporting Alzheimer’s development for VNA-318
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Poolbeg Pharma doses first patient in POLB 001 trial to prevent cytokine release syndrome
read more
Medical devices,Research & Development
Organic semiconductor breakthrough could improve wearable healthcare sensors
read more
Biotech & Pharma Business,Clinical & Regulatory,Medical devices,Research & Development
En Carta Diagnostics secures €5M to advance at-home molecular testing
read more
Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Therapeutic Areas
Theranica expands Nerivio migraine device coverage to more than half of insured Americans
read more
Drug Discovery & Development,Research & Development,Therapeutic Areas
mRNA therapy shows potential for treating autoimmune diseases
read more
Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Australian Phase 1 trial begins for CAR-T therapy targeting solid tumours
read more
Advanced Therapies,Drug Discovery & Development,Research & Development,Therapeutic Areas
Atsena selects clinical candidate for Stargardt disease gene therapy
read more
Clinical & Regulatory,Digital & Data,Genomics and sequencing
Quest Diagnostics expands access to molecular cancer testing through OncoEMR
read more
Digital & Data,Medical devices,Research & Development
Seegene launches global million-patient study of syndromic PCR testing
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics
Fonseca Biosciences launches XTORO after FDA clears US commercial manufacturing
read more
Advanced Therapies,Digital & Data,Manufacturing & Supply Chain
Autolomous and Cellular Origins integrate platforms for automated cell therapy manufacturing
read more

ProMIS reports first human evidence of PMN310 target engagement in Alzheimer’s disease

Erasca reports encouraging Phase 1 data for ERAS-0015 and outlines Phase 3 cancer trials

Tenpoint submits UK application for presbyopia eye drop YUVEZZI

Q32 Bio reports positive Phase 2 alopecia areata trial results for bempikibart

Vandria reports Phase 1 data supporting Alzheimer’s development for VNA-318

Poolbeg Pharma doses first patient in POLB 001 trial to prevent cytokine release syndrome

Organic semiconductor breakthrough could improve wearable healthcare sensors

En Carta Diagnostics secures €5M to advance at-home molecular testing

Theranica expands Nerivio migraine device coverage to more than half of insured Americans

mRNA therapy shows potential for treating autoimmune diseases

Australian Phase 1 trial begins for CAR-T therapy targeting solid tumours

Atsena selects clinical candidate for Stargardt disease gene therapy

Quest Diagnostics expands access to molecular cancer testing through OncoEMR

Seegene launches global million-patient study of syndromic PCR testing

Fonseca Biosciences launches XTORO after FDA clears US commercial manufacturing

Autolomous and Cellular Origins integrate platforms for automated cell therapy manufacturing

main menu

recent posts

Nucleome strengthens 3D genomics platform with US patent for Micro Capture-C technology

Novogene expands Cambridge Omics Centre with untargeted metabolomics service

ProMIS reports first human evidence of PMN310 target engagement in Alzheimer’s disease

get connected